AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Artelo Biosciences Soars 6.84% on Promising Depression Drug Data
Generated by AI AgentAinvest Pre-Market Radar
Tuesday, Jul 8, 2025 7:55 am ET1min read
Artelo Biosciences' stock surged 6.84% in pre-market trading on July 8, 2025, driven by positive preclinical data for its drug candidate ART12.11 in a stress-induced depression model.
Artelo Biosciences reported that ART12.11 significantly restored key depression-related behaviors to baseline levels in a stressed rodent model. The drug demonstrated efficacy comparable to Pfizer's antidepressant Zoloft, indicating its potential as a novel treatment for depression.
The company's announcement highlighted ART12.11's ability to improve depression-related behaviors and reverse cognitive deficits associated with chronic stress. This positive preclinical data has generated significant investor interest, contributing to the stock's pre-market surge.
Artelo Biosciences' preclinical study compared ART12.11, a cocrystal combining cannabidiol and tetramethylpyrazine, to sertraline in male rats exposed to chronic stress over 28 days. The results showed that ART12.11 effectively restored key depression-related behaviors, suggesting its potential as a new therapeutic option for depression.
Ainvest Pre-Market Radar
Get the scoop on pre-market movers and shakers in the US stock market.
Latest Articles
SEALSQ Surged 8.29% Driven by 2026–2030 Roadmap for Silicon-Based Quantum Computing Systems
Dec.19 2025
Serve Robotics (SERV) Surges 5.97% on Bullish Oppenheimer Note
Dec.19 2025
AXT Inc. shares surge 13.35% on renewed earnings upside speculation amid supply chain adjustments
Dec.19 2025
PROK surged 5.11% on Dec. 19 2025 after HC Wainwright upgraded to Buy rating
Dec.19 2025
Tesla shares surge 3.45% as SpaceX orders 1,000-2,000 Cybertrucks for Starbase facility.
Dec.19 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet